WORLD-BRANDING-AWARDS
7.11.2022 14:26:37 CET | Business Wire | Press release
The fifteenth edition of the World Branding Awards saw over 3,500 brands from more than 45 countries nominated as “Brand of the Year”. Of these, less than 250 were declared Winners. The Awards Ceremony welcomed over 100 guests from around the world to celebrate the success and achievements of some of the World’s Best Brands, at the home of the awards, Kensington Palace.
Lurpak, Club Med, Yakult, Spotify, CoCo, Ikea, Amazon, Netflix, Neutrogena, Lego, Cadbury, Johnnie Walker, Ferrari, and Hennessy were announced as Global Winners at the prestigious awards ceremony.
Winners from Denmark include Bedre Naetter, Lagkagehuset, Bang & Olufsen, Tivoli Gardens. Other National Tier winners include Sokos Hotels (Finland), Carrefour (France), Haribo (Germany), Pertamina (Indonesia), Tuskys (Kenya), Amarula (South Africa). Silent Night (UK), and Toast Box (Singapore) to name a few.
Just 17 brands were selected to receive the Regional Tier award this year; Bosch, Media Markt, Sennheiser, SoundCloud, Al Abraaj Restaurants, Huawei, Carrefour, Optical 88, MR. D.I.Y., Elkjøp, Aramax, BreadTalk, Naturgy, H&M, Walrus Pump, Gems Pavilion, and CBRE. These brands were voted as the consumers favourite brand in 4 or more countries across 3 or more areas in a specific geographic region.
“The ceremony is a celebration of some of the best brands from across the globe. The Awards acknowledge the tireless effort put in by the brand's teams that build and maintain presence in an ever-evolving market” said Mr Danny Pek, Executive Director, World Branding Forum.
“This year over 150,000 consumers participated in the nomination process globally. On average there are only 5 winning brands in each country, further proving that winning a World Branding Award is indeed, a remarkable achievement” said Mr Richard Rowles, Chairman of the World Branding Forum.
The event was hosted by renowned television presenter, Jemma Forte and featured an exclusive insight into the future consumer provided by Chris Sanderson, Co-Founder of 'The Future Laboratory' the renowned consumer insights and trend forecasting consultancy.
For more information and the full list of winners, visit awards.brandingforum.org.
About the World Branding Awards
The World Branding Awards is the premier awards of the World Branding Forum, a registered non-profit organisation. The Awards recognises the achievements of some of the world’s best brands. For more information, visit https://awards.brandingforum.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005342/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom